NewsBenzingaNovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia Benzinga 2026.10.20 11:03 (GMT+0) Open on Benzinga Other news ‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead Trump Administration Sued by Ecuadorian Fishermen Over Pacific Drone Strike: ‘We’re Alive by the Grace of God’ Micron Technology (MU) Stock Is Trending After Hours: Here's Why Kevin O’Leary Says Nvidia Needs Leader Who Can Manage ‘International Pressure’ as Crypto Punters Raise Odds of NVDA Stock Hitting $180 By Month-End Anthony Scaramucci Blasts Trump on FAA Meltdown: ‘Why Don’t We Start Focusing on Ourselves Now?’
‘Not Under Systemic Attack’: Marco Rubio Says ‘Zero Evidence’ Microsoft, JPMorgan and FAA Outages Due to Hostile Actors
Can Colette Kress Fill Jensen Huang’s Shoes? Nvidia Posts $116 Billion Quarter, but Analyst Sees ‘Bigger Test’ Ahead
Trump Administration Sued by Ecuadorian Fishermen Over Pacific Drone Strike: ‘We’re Alive by the Grace of God’
Kevin O’Leary Says Nvidia Needs Leader Who Can Manage ‘International Pressure’ as Crypto Punters Raise Odds of NVDA Stock Hitting $180 By Month-End